Abstract
NF-κB2/p100 (p100) is an inhibitor of κB (IκB) protein that is partially degraded to produce the NF-κB2/p52 (p52) transcription factor. Heterozygous NFKB2 mutations cause a human syndrome of immunodeficiency and autoimmunity, but whether autoimmunity arises from insufficiency of p52 or IκB function of mutated p100 is unclear. Here, we studied mice bearing mutations in the p100 degron, a domain that harbors most of the clinically recognized mutations and is required for signal-dependent p100 degradation. Distinct mutations caused graded increases in p100-degradation resistance. Severe p100-degradation resistance, due to inheritance of one highly degradation-resistant allele or two subclinical alleles, caused thymic medullary hypoplasia and autoimmune disease, whereas the absence of p100 and p52 did not. We inferred a similar mechanism occurs in humans, as the T cell receptor repertoires of affected humans and mice contained a hydrophobic signature of increased self-reactivity. Autoimmunity in autosomal dominant NFKB2 syndrome arises largely from defects in nonhematopoietic cells caused by the IκB function of degradation-resistant p100.
| Original language | English |
|---|---|
| Article number | e20200476 |
| Number of pages | 19 |
| Journal | Journal of Experimental Medicine |
| Volume | 218 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 27 Oct 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- autoimmunity
Projects
- 4 Finished
-
How does NF-kB2 regulate thymic selection to prevent organ-specific autoimmune disease?
Daley, S. (Primary Chief Investigator (PCI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/16 → 31/12/19
Project: Research
-
De novo mutations and the pathogenesis of childhood-onset autoimmune disease
Daley, S. (Chief Investigator (CI)), Roscioli, T. (Chief Investigator (CI)), Deenick, E. K. (Chief Investigator (CI)), Gray, P. E. (Chief Investigator (CI)), Craig, M. (Chief Investigator (CI)), Wong, M. (Chief Investigator (CI)), Teo, J. (Chief Investigator (CI)), Gunton, J. (Chief Investigator (CI)), Andrews, T. D. (Chief Investigator (CI)) & Goodnow, C. (Primary Chief Investigator (PCI))
1/01/16 → 31/12/19
Project: Other
-
Centre for Personalised Immunology
Vinuesa, C. G. (Primary Chief Investigator (PCI)), Cook, M. C. (Chief Investigator (CI)), Fulcher, D. A. (Chief Investigator (CI)), Alexander, S. I. (Chief Investigator (CI)), Kitching, R. (Chief Investigator (CI)), Enders, A. (Chief Investigator (CI)), Casellas, R. (Chief Investigator (CI)), Field, M. A. (Chief Investigator (CI)), Schwarz, K. (Chief Investigator (CI)) & Andrews, T. D. (Chief Investigator (CI))
NHMRC - National Health and Medical Research Council (Australia)
1/12/14 → 30/11/19
Project: Research
Equipment
-
FlowCore (FLOW)
Fryga, A. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
-
Monash Animal Research Platform (MARP)
Findlay, C. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
-
Monash Genomics & Bioinformatics Platform (MGBP)
Perlaza-Jimenez, L. (Manager) & Ng, N. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver